John M. Burke, MD
Aurora, Colorado 80012
Centennial, Colorado 80112
Englewood, Colorado 80113
Littleton, Colorado 80120
About John M. Burke, MD
Dr. Burke is a board-certified hematologist and medical oncologist who joined RMCC in 2003. He specializes in blood cancers and non-cancerous blood disorders, with an emphasis on lymphomas, chronic lymphocytic leukemia, and multiple myeloma. Dr. Burke is considered a national and international expert in these diseases. He is very active in clinical research, helping to develop new therapies for these cancers. As a result, Dr. Burke has published numerous articles in peer-reviewed medical journals describing the findings of these clinical trials. He also spends considerable time educating other healthcare professionals and students about hematological malignancies, giving lectures nationally and internationally. He meets regularly with pharmaceutical companies to advise them on the best way to develop new treatments for patients with blood cancers. Because of his ongoing participation in clinical research, Dr. Burke is able to offer the latest therapies for patients with blood cancers. He places a high value on patient autonomy; that is, his patients are always given the opportunity to make informed decisions about their own medical care.
Clinical Care Expertise
- Blood Disorders and Diseases
- Bleeding & Clotting Disorders
- Deep vein thrombosis
- Pulmonary embolism
- Pregnancy-Related Blood Disorders
- Antiplatelet and Anticoagulant Management
- Hematologic Oncology
- Acute Lymphoblastic Leukemia (ALL)
- Chronic Myeloid Leukemia (CML)
- Chronic Lymphocytic Leukemia (CLL)
- Hairy Cell Leukemia (HCL)
- Hodgkin Lymphoma
- Non-Hodgkin Lymphomas
- Follicular Lymphoma
- Diffuse Large B-Cell Lymphoma
- Peripheral T-Cell Lymphoma and Other T-Cell Lymphomas
- Lymphoproliferative Disorders
- Plasma Cell Disorders
- Multiple myeloma
- Smoldering myeloma
- Monoclonal gammopathy of undetermined significance (MGUS)
Hematology & Medical Oncology, Memorial Sloan-Kettering Cancer Center, New York City, NY
Internal Medicine, University of California San Francisco, San Francisco, CA
Baylor College of Medicine, Houston, TX
Patient Care Philosophy
I believe that the role of physicians is to educate patients and to help them make the best decisions possible regarding their own care. The idea that “physicians know best” and should dictate treatment to patients is archaic. Instead, physicians serve as teachers by educating patients about their diseases and their treatment options and helping patients select the best treatment for their situation.
I focus my clinical practice on patients with cancers of the blood (lymphomas, leukemias, and myeloma). I emphasize to patients the importance of participating in clinical trials whenever possible – both to ensure that they are receiving the most up-to-date, cutting-edge treatments for their diseases and to help advance the field of oncology.
American Society of Clinical Oncology
American Society of Clinical Oncology Clinical Well-Being Task Force
American Society of Clinical Oncology Ethics Committee
American Society of Hematology
HealthOne/Sarah Cannon Cancer Governance Board
Leukemia Lymphoma Society Board of Trustees, Rocky Mountain Chapter
US Oncology Early Development (Phase I) Research Committee
US Oncology Hematology Research Committee, Associate Chair
US Oncology Pathways Task Force Committee
US Oncology Research Executive Committee
September 8, 2021. Invited Lecturer, Chronic Lymphocytic Leukemia. Society of Hematologic Oncology, Houston, TX.
April 24, 2021. Presenter, Chronic Lymphocytic Leukemia. Leukemia and Lymphoma Society Rocky Mountain Blood Cancer Conference.
March 2021. Presenter, Chronic Lymphocytic Leukemia. Highlights of ASH Meeting.
November 12, 2020. Presenter, Diffuse Large B-cell Lymphoma. CASES Conference.
November 4, 2020. Presenter, Follicular Lymphoma. Curio Interactive Local Workshop.
October 28, 2020. Presenter, Chronic Lymphocytic Leukemia. Clinical Care Options Virtual Webinar.
October 13, 2020. Presenter, Chronic Lymphocytic Leukemia. PRIME CLL Collaborative Learning Session.
September 16, 2020. Presenter, “Ask the Doctor About Lymphoma.” Lymphoma Research Foundation.
June 19, 2020. Speaker, Evolving Therapies in Chronic Lymphocytic Leukemia. OncLive Video.
Burke JM et al. Real-world characteristics of patients with peripheral T-cell lymphoma receiving frontline brentuximab vedotin with chemotherapy: a retrospective analysis with propensity score matching. American Society of Hematology 2020, abstract 3418.
Belada D et al. A phase 1b, open-label, randomized study to assess safety and preliminary efficacy of tafasitamab (MOR208) or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma: analysis of the safety run-in phase. American Society of Hematology 2020, abstract 3028.
Flinn IW et al. Debulking regimens prior to initiating venetoclax therapy in untreated patients with chronic lymphocytic leukemia: interim results from a phase 3b study. American Society of Hematology 2020, abstract 3151.
Gribben JG et al. Umbralisib plus ublituximab (U2) is superior to Obinutuzumab plus chlorambucil (O+Chl) in patients with treatment naïve (TN) and relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): results from the phase 3 Unity-CLL study. American Society of Hematology 2020, abstract 543.
Philllips TJ et al. Real-world characteristics of patients with classical Hodgkin lymphoma receiving frontline brentuximab vedotin with chemotherapy: a retrospective analysis with propensity score matching. American Society of Hematology 2020, abstract 2499.
Shadman M et al. Phase 2 study of zanubrutinib in patients with relapsed/refractory B-cell malignancies intolerant to ibrutinib/acalabrutinib. American Society of Hematology 2020, abstract 2947.
Shah NN et al. Preliminary results of an ongoing phase 1 dose escalation study of the novel anti-CD74 antibody drug conjugate (ADC), STRO-001, in patients with B-cell non-Hodgkin lymphoma. American Society of Hematology 2020, abstract 3030.
Zinzani PL et al. Umbralisib, the once daily dual inhibitor of PI3Kd and casein kinase-1e demonstrates clinical activity in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results from the phase 2 global Unity-NHL trial. American Society of Hematology 2020, abstract 2934.
Burke JM, Morschhauser F, Andorsky D, Lee C, Sharman JP. Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin. Expert Review of Clinical Pharmacology 2020; 13(10): 1073-83.
Burke JM, Shustov A, Essell J, Patel-Donnelly D, Yang J, Chen R, Ye W, Shi W, Assouline S, Sharman J. An open-label, phase II trial of entospletinib (GS-9973), a selective spleen tyrosine kinase inhibitor, in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2018; 18(8):e327-e331.
Burke JM, van der Jagt RHC, Kahl BS, Wood P, Hawkins, TE, MacDonald D, Hertzberg M, Simpson D, Craig M, Kolibaba K, Issa S, Munteanu M, Victor TW, Flinn IW. Differences in quality of life between bendamustine-rituximab and R-CHOP/R-CVP in patients with previously untreated advanced indolent non-Hodgkin lymphoma or mantle cell lymphoma. Clinical Lymphoma, Myeloma, & Leukemia 2016; (16(4):182-190.
Burke JM, Van der Jagt RHC, Flinn IW, Craig MD, Chen L, Morganroth J, Munteanu MC, MacDonald DA. Effect of bendamustine in combination with rituximab on QT interval duration in patients with advanced de novo indolent non-Hodgkin or mantle cell lymphoma. Cancer Chemotherapy and Pharmacology 2015; 76(1):211-216.
Darwish M, Burke JM, Hellriegel E, Robertson P, Phillips L, Ludwig E, Munteanu MC, Bond M. An evaluation of the potential for drug-drug interactions between bendamustine and rituximab in indolent non-Hodgkin lymphoma and mantle cell lymphoma. Cancer Chemother Pharmacol 2014; 73(6):1119-27.
Flinn IW, van der Jagt R, Kahl B, Wood P, Hawkins T, MacDonald D, Simpson D, Kolibaba K, Issa S, Chang J, Trotman J, Hallman D, Chen L, Burke JM. First-line treatment of patients with indolent non-Hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study. J Clin Oncol 2019; 37(12):984-91.
Flinn IW, van der Jagt R, Kahl BS, Wood P, Hawkins TE, MacDonald D, Hertzberg M, Kwan Y, Simpson D, Craig M, Kolibaba K, Issa S, Clementi R, Hallman DM, Munteanu M, Chen L, Burke JM. Open-label, randomized, noninferiority study of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of advanced indolent NHL or MCL: the BRIGHT study. Blood 2014; 123(19):2944-52.
Fowler NH, Samaniego F, Jurczak W…Burke JM, et al. Umbralisib, a dual PI3K /CK1 inhibitor, in patients with relapsed or refractory indolent lymphoma [published online ahead of print March 8, 2021]. J Clin Oncol 2021.
Grunwald MR, Kuter DJ, Altomare I, Burke JM, et al. Treatment patterns and blood counts in patients with polycythemia vera treated with hydroxyurea in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leukemia 2020; in press.
Grunwald MR, Burke JM, Kuter DJ, Gerds AT, Stein B, Walshauser MA, Parasuraman S, Colucci P, Paranagama D, Savona MR, Mesa R. Symptom burden and blood counts in patients with polycythemia vera in the United States: an analysis from the REVEAL study. Clin Lymphoma Myeloma Leuk 2019; 19(9):579-84.e1.
Hlubocky FJ, Symington BE, McFarland, …Burke JM…et al. Impact of the COVID-19 pandemic on oncologist burnout, emotional well-being, and moral distress: considerations for the cancer organization’s response for readiness, mitigation, and resilience. JCO Oncology Practice 2021, online.
Munteanu MC, Burke JM. Barriers to lymphoma clinical practice guideline adherence: a pilot mixed-methods research study. J Clin Pathways 2019; 5(3):31-38,S1-3.
Sharman JP, Brander DM, Mato AR…Burke JM, et al. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomized trial. Lancet Haematology, online February 2021.
Sharman JP, Burke JM, Yimer HA, Boxer MA, Babu S, Li J, Mun Y, Danilov AV. Phase 2 multicenter GIBB study of obinutuzumab plus bendamustine in previously untreated patients with chronic lymphocytic leukemia. Leukemia & Lymphoma, published online 26 Nov 2020.
Sharman JP, Farber CM, Mahadevan D, Schreeder MT, Brooks HD, Kolibaba KS, Fanning S, Klein L, Greenwald DR, Sportelli P, Miskin HP, Weiss MS, and Burke JM. Ublituximab (TG-1101), a novel glycoengineered anti-CD20 antibody, in combination with ibrutinib is safe and highly active in patients with relapsed and/or refractory chronic lymphocytic leukemia: results of a phase 2 trial. British Journal of Hematology 2017, 176(3):412-20.
Sharman JP, Wheler JJ, Einhorn L, Dowlati A, Shapiro GI, Hilton J, Burke JM, Siddiqi T, Whiting N, Jalal SI. A phase 2, open-label study of brentuximab vedotin in patients with CD30-expressing solid tumors. Investigational New Drugs 2019; 37(4):738-47.
Vitolo U, Trneny M, Belada D, Burke JM, et al. Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma. Journal of Clinical Oncology 2017; 2017; 35(31):3529-37.
Wilfong L, Ginsburg A, Hoverman JR, Burke JM, Busby LT, Hsieh A, Konduri K, Neubauer MA. Treatment pathways for first-line metastatic non-small cell lung cancer: cost and survival. J Clin Pathways 2020; 6(8):52-7.
Yimer H, Melear J, Faber E, Bensinger WI, Burke JM, Narang M, Stevens D, Gunawardena S, Lutska Y, Qi K, Ukropec J, Qi M, Lin TS, and Rifkin RM. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. Brit J Haematol 2019; 185(3).